Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant targeted therapy or immunotherapy for stage III non-small cell lung cancer
ChiCTR2000032130Phase 4Not yet recruiting
- Sponsor
- Department of Thoracic Surgery, Shanghai Pulmonary Hospital of Tongji University
- Start
- Jun 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of carboplatin, gemcitabine and pemetrexed in non-small cell lung cancer (NSCLC) (3 cohorts), sponsored by Department of Thoracic Surgery, Shanghai Pulmonary Hospital of Tongji University. Primary endpoints: major pathologic response and objective response rate. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
carboplatingemcitabinepemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000032130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032130.